Search Within

Komal Lachhman Jhaveri

Formats
  1. Meeting Abstract (120)
  2. Journal Article (88)
  3. Review (5)
  4. Editorial (2)
  5. Correspondence (1)
  6. Guidelines (1)
Groups
  1. Breast Medicine Service (217)
  2. Department of Medicine (217)
  3. Solid Tumor Oncology Division (217)
  4. GSK Faculty (58)
  5. Survivorship Research (45)
  6. Epidemiology and Biostatistics (44)

More Groups

People
  1. Shanu Modi (35)
  2. Sarat Chandarlapaty (28)
  3. Pedram Razavi (25)
  4. Clifford Hudis (24)
  5. Sujata Patil (22)
  6. Gary Ulaner (18)

More People

Years
  1. 2025 (23)
  2. 2024 (34)
  3. 2023 (17)
  4. 2022 (24)
  5. 2021 (26)
  6. 2020 (28)

More Years

Publications
  1. Journal of Clinical Oncology (66)
  2. Cancer Research (33)
  3. Annals of Oncology (22)
  4. Clinical Cancer Research (10)
  5. European Journal of Cancer (5)
  6. New England Journal of Medicine (5)

More Publications

Publishers
  1. American Society of Clinical Oncology (69)
  2. American Association for Cancer Research (47)
  3. Oxford University Press (23)
  4. Elsevier Inc. (16)
  5. Springer (7)
  6. Nature Publishing Group (6)

More Publishers

Results (217)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Molecularly targeted therapies for triple negative breast cancer: History, advances, and future directions
    Review

    Mai, N.; Abuhadra, N.; Jhaveri, K.
    Clinical Breast Cancer (2023)

    Fulltext@MSK | Save
  • Matching-adjusted indirect comparison of PFS and OS comparing ribociclib plus letrozole versus palbociclib plus letrozole as first-line treatment of HR+/HER2− advanced breast cancer
    Journal Article

    Jhaveri, K.; O’Shaughnessy, J.; Fasching, P. A.; Tolaney, S. M.; Yardley, D. A.; Sharma, V. K.; Biswas, C.; Thuerigen, A.; Pathak, P.; Rugo, H. S.
    Therapeutic Advances in Medical Oncology (2023)

    Fulltext@MSK | Save
  • Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): A randomised, open-label, multicentre, phase 3 trial
    Journal Article

    Rugo, H S.; Bardia, A.; Marmé, F.; Cortés, J.; Schmid, P.; Loirat, D.; Trédan, O.; Ciruelos, E.; Dalenc, F.; Gómez Pardo, P.; more...
    Lancet (2023)

    Fulltext@MSK | Save
  • Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: Outcomes and biomarker analysis from the SUMMIT trial
    Journal Article

    Jhaveri, K.; Eli, L. D.; Wildiers, H.; Hurvitz, S. A.; Guerrero-Zotano, A.; Unni, N.; Brufsky, A.; Park, H.; Waisman, J.; Yang, E. S.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • evERA Breast Cancer (BC): Phase III study of giredestrant + everolimus vs exemestane + everolimus in patients (pts) with estrogen receptor-positive, HER2-negative locally advanced or metastatic BC (ER+, HER2– LA/mBC)
    Meeting Abstract

    Mayer, E. L.; Tolaney, S. M.; Brufsky, A.; Gradishar, W. J.; Jhaveri, K. L.; Martin, M.; Moscetti, L.; Schneeweiss, A.; Vidal, G. A.; Cortazar, P.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Real-world clinical outcomes in patients (pts) with HR+/HER2- metastatic breast cancer (mBC) treated with chemotherapy (CT) in the United States (US)
    Meeting Abstract

    Tolaney, S. M.; Punie, K.; Kurian, A. W.; Ntalla, I.; Verret, W.; Sadetsky, N.; Sjekloca, N.; Stokes, M.; Jhaveri, K. L.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • HER2 persistence after treatment with T-DXd in breast and gastrointestinal cancers
    Meeting Abstract

    Drago, J. Z.; Pareja, F.; Jhaveri, K. L.; Walsh, E. M.; Ku, G. Y.; Maron, S. B.; Janjigian, Y. Y.; Robson, M. E.; Reis-Filho, J. S.; Modi, S.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Capivasertib (C) and fulvestrant (F) for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2– advanced breast cancer (ABC): Characterization and management of common adverse events (AEs) from the phase 3 CAPItello-291 trial
    Meeting Abstract

    Rugo, H. S.; Oliveira, M.; Howell, S. J.; Dalenc, F.; Cortes, J.; Gomez, H. L.; Hu, X.; Iwata, H.; Jhaveri, K. L.; Loibl, S.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC)
    Meeting Abstract

    Tolaney, S. M.; Bardia, A.; Marmé, F.; Cortés, J.; Schmid, P.; Loirat, D.; Tredan, O.; Ciruelos, E. M.; Dalenc, F.; Gómez Pardo, P.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Capivasertib in hormone receptor-positive advanced breast cancer
    Journal Article

    Turner, N. C.; Oliveira, M.; Howell, S. J.; Dalenc, F.; Cortes, J.; Gomez Moreno, H. L.; Hu, X.; Jhaveri, K.; Krivorotko, P.; Loibl, S.; more...
    New England Journal of Medicine (2023)

    Fulltext@MSK | Save